Germline multigene panel testing in gynecological cancer

*Correspondence sayaka-u@okayama-u.ac.jp (Sayaka Ueno) Abstract Multi-gene panel testing (MGPT) has become widely used in clinical practice. MGPT allows a set of genes to be tested simultaneously, making it a powerful, timeand cost-effective tool for detecting genetic variants. The purposes of identifying germline pathogenic variants is threefold: diagnosis, prevention, and treatment. Germline variants in certain genes cause hereditary tumor syndromes. Diagnosing hereditary tumors enable to predict the types of cancer that may develop in the future. The blood relatives of those diagnosed may also suffer from the same hereditary tumor syndrome. For such individuals, medical intervention tailored to their condition can reduce the incidence of cancer or help in cancer detection in the early stages. Diagnosis of hereditary tumors may also change the cancer treatment strategy for the diagnosed patient. To date, more than 100 genes have been found to have a predisposition to cancer. The type of cancer one develops, the risk of developing it, and the possible preventive strategy differs among genes. The association of some genes with cancer predisposition has not yet been fully confirmed. Nowadays, various types of MGPTs are available, and the genes included differ among the tests. In addition, no consensus has been reached on which genes to be included in MGPT. This review is aimed to summarize the advantages and limitations of MGPT along with some practical considerations while performing MGPT and the gynecological tumors associated with genes commonly included in MGPT.

• Publication year

  2022

• Venue

  European Journal of Gynaecological Oncology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.22514/ejgo.2022.008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)

  2021cited by this paper
• Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

  2021cited by this paper
• NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 1.2021.

  2021cited by this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cited by this paper
• Current Testing Guidelines: A Retrospective Analysis of a Community-Based Hereditary Cancer Program

  2021cited by this paper
• Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

  2021influential reference
• Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome

  2020cited by this paper
• Rhabdoid Tumor Predisposition Syndrome

  2020cited by this paper
• Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.

  2020cited by this paper
• One in seven pathogenic variants can be challenging to detect by NGS: an analysis of 450,000 patients with implications for clinical sensitivity and genetic test implementation

  2020cited by this paper
• Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines

  2020cited by this paper
• Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer

  2020influential reference
• Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

  2020cited by this paper
• Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma

  2020cited by this paper
• Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

  2019cited by this paper
• Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

  2019cited by this paper
• Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.

  2019cited by this paper
• Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1.

  2019cited by this paper
• The effects of genomic germline variant reclassification on clinical cancer care

  2019cited by this paper
• Cancer susceptibility gene mutations in type I and II endometrial cancer.

  2019cited by this paper
• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

  2019cited by this paper
• A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next‐generation sequencing hereditary pan‐cancer panel are acquired somatically

  2019cited by this paper
• Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

  2019cited by this paper
• A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients

  2019influential reference
• Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment

  2019cited by this paper
• Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.

  2019cited by this paper
• Germline pathogenic variants identified in women with ovarian tumors.

  2018cited by this paper
• Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark

  2018cited by this paper
• Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer

  2018influential reference
• Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups

  2018cited by this paper
• DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies

  2018cited by this paper
• Pathogenic Germline Variants in 10,389 Adult Cancers.

  2018influential reference
• Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG)

  2018cited by this paper
• Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

  2018cited by this paper
• Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing

  2018cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

  2017cited by this paper
• Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.

  2017cited by this paper
• Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study

  2017cited by this paper
• Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer

  2017cited by this paper
• Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.

  2017cited by this paper
• DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.

  2016cited by this paper
• Inherited Mutations in Women With Ovarian Carcinoma.

  2016influential reference
• Ovarian cancer in Lynch syndrome; a systematic review.

  2016cited by this paper
• The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.

  2016cited by this paper
• Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort

  2016cited by this paper
• Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

  2016cited by this paper
• Successful pregnancy in a Peutz–Jeghers syndrome patient with lobular endocervical glandular hyperplasia

  2015cited by this paper
• Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing

  2015cited by this paper
• ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

  2015cited by this paper
• Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.

  2015cited by this paper
• American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome.

  2015cited by this paper
• Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.

  2015cited by this paper
• Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines.

  2015cited by this paper
• A tumor of the uterine cervix with a complex histology in a Peutz-Jeghers syndrome patient with genomic deletion of the STK11 exon 1 region.

  2014cited by this paper
• Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations.

  2014influential reference
• Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer.

  2014cited by this paper
• Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4

  2014cited by this paper
• Recurrent SMARCA4 mutations in small cell carcinoma of the ovary

  2014cited by this paper
• Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type

  2014cited by this paper
• DICER1: mutations, microRNAs and mechanisms

  2014cited by this paper
• Breast-cancer risk in families with mutations in PALB2.

  2014cited by this paper
• MYRIAD AFTER MYRIAD: THE PROPRIETARY DATA DILEMMA.

  2014cited by this paper
• After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene Patents

  2014cited by this paper
• A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment

  2014cited by this paper
• The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.

  2013cited by this paper
• Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.

  2013cited by this paper
• Lobular endocervical glandular hyperplasia and peritoneal pigmentation associated with Peutz-Jeghers syndrome due to a germline mutation of STK11.

  2012cited by this paper
• Peutz-Jeghers syndrome-associated atypical mucinous proliferation of the uterine cervix: a case of minimal deviation adenocarcinoma ('adenoma malignum') in situ.

  2012cited by this paper
• Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations

  2012cited by this paper
• Lifetime Cancer Risks in Individuals with Germline PTEN Mutations

  2012cited by this paper
• Risks of less common cancers in proven mutation carriers with lynch syndrome.

  2012cited by this paper
• BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

  2012influential reference
• DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome

  2011cited by this paper
• Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

  2011influential reference
• Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA )

  2011cited by this paper
• Peutz–Jeghers syndrome: a systematic review and recommendations for management

  2010cited by this paper
• DICER1 Mutations in Familial Pleuropulmonary Blastoma

  2009cited by this paper
• Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1

  2009cited by this paper
• Peutz-Jeghers syndrome

  2008cited by this paper
• Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.

  2006cited by this paper
• PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study

  2006cited by this paper
• DHPLC Analysis of patients with Nevoid Basal Cell Carcinoma Syndrome reveals novel PTCH missense mutations in the sterol‐sensing domain

  2005cited by this paper
• Neurocutaneous Disorders: Nevoid basal cell carcinoma (Gorlin) syndrome

  2004cited by this paper
• Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome

  2004cited by this paper
• Gastrointestinal immunophenotype in adenocarcinomas of the uterine cervix and related glandular lesions: a possible link between lobular endocervical glandular hyperplasia/pyloric gland metaplasia and ‘adenoma malignum’

  2004cited by this paper
• The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.

  2001cited by this paper
• Very high risk of cancer in familial Peutz-Jeghers syndrome.

  2000cited by this paper
• A serine/threonine kinase gene defective in Peutz–Jeghers syndrome

  1998cited by this paper
• Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase

  1998cited by this paper
• Localization of the gene for Cowden disease to chromosome 10q22–23

  1996influential reference
• DICER1 Tumor Predisposition

  1993cited by this paper
• Hereditary Colorectal Cancer

  1990influential reference
• Adenoma Malignum (Minimal Deviation Adenocarcinoma) of the Uterine Cervix: A Clinicopathological and Immunohistochemical Analysis of 26 Cases

  1989influential reference
• Female genital tract tumors in Peutz-Jeghers syndrome.

  1986influential reference
• Ovarian sex cord tumor with annular tubules. Review of 74 cases including 27 with Peutz‐Jeghers syndrome and four with adenoma malignum of the cervix

  1982influential reference

• No citing papers are available for this paper.